Consensus AtriCure, Inc.

Stocks

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 14:15:45 2026-09-03 EDT			5-day change	1st Jan Change
52.46 ^USD	-0.25%		+7.04%	+33.32%

09-02	Needham Raises Price Target on AtriCure to $64 From $45, Keeps Buy Rating	MT
08-26	Atricure Insider Sold Shares Worth $458,099, According to a Recent SEC Filing	MT

Evolution of the Average Target: AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

d38db49d64c854055dfc87216064.m6o6KO-kDirJ3y-g4liLaTn9rXeOfn0IOUpSiYcw6u0.ouZVUJbQbEyZjXzY1iHtImHNmxbLUxQ9fAYLwshjg6_E2GJOhsN0aaDnbg~fc053bc65a11a94e6eba1ea7f698f4f3

Analysts' recommendations: AtriCure, Inc.

09-02	Needham Raises Price Target on AtriCure to $64 From $45, Keeps Buy Rating	MT
07-28	UBS Adjusts Price Target on AtriCure to $50 From $55, Maintains Buy Rating	MT
02-18	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
02-18	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT
02-11	AtriCure Shares Fall After JPMorgan Downgrade	MT
02-11	Top Midday Decliners	MT
02-11	JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48	MT
25-07-30	Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating	MT
25-07-29	AtriCure Q2 revenue beats estimates	RE
25-04-30	UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating	MT
25-03-28	Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating	MT
25-02-13	Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating	MT
24-10-30	UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating	MT
24-07-31	Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating	MT
24-05-02	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
24-04-23	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
24-02-16	UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	MT
24-02-16	Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	MT
24-02-16	Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	MT
24-01-22	UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	MT
23-10-23	JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	MT
23-09-29	UBS Initiates AtriCure With Buy Rating, Price Target is $56	MT
23-07-26	Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	MT
23-05-03	Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	MT
23-02-22	BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ATRICURE, INC.					-1.76%
	ABBOTT LABORATORIES					+8.81%
	MEDTRONIC PLC					+12.22%
	CENCORA, INC.					+9.8%
	HOYA CORPORATION					+25.58%
	BECTON, DICKINSON AND COMPANY					+4.34%
	DEXCOM, INC.					+4.94%
	MEDLINE INC.					+22.86%
	WEST PHARMACEUTICAL SERVICES, INC.					+18.13%
	TERUMO CORPORATION					+26.9%
	Average					+13.18%
	Weighted average by Cap.					+12.24%